Laboratory Program News
April 30, 2012
The BC-CfE laboratory program took home the award for science, research and technology at the bi-annual AccolAIDS awards gala honouring those in the HIV/AIDS community in BC.
March 30, 2011
|
Vancouver Sun
Genetic testing methodologies developed by the BC-CfE research laboratory are being used around the world to improve HIV treatment.
April 9, 2010
|
AIDSmeds.com
Only 17 percent of people starting treatment with modern-day antiretroviral (ARV) regimens developed HIV drug resistance over eight years of therapy, according to an analysis from a British cohort study published in the May 1 issue of the journal Clinical Infectious Diseases.
January 19, 2010
|
HIVandHepatitis.com
Over time, HIV can develop mutations that confer resistance to antiretroviral agents. This typically happens, for example, if a drug is not potent enough to fully suppress viral replication or if a patient has poor adherence.
January 12, 2010
|
CBC
People being treated for HIV are less likely now to develop drug-resistant infections, according to a British Columbia study on changes in drug therapy.
January 11, 2010
|
Vancouver Sun
The number of HIV patients who develop drug-resistant infections is dropping dramatically in B.C. as a result of improved treatments, says the author of a newly published study on the issue.
January 11, 2010
|
National Post
A new B.C. study shows a dramatic decrease in the number of HIV patients developing resistance to anti-retroviral drugs.
January 5, 2010
|
Aidsmap
There has been a drastic fall in the incidence of new cases of drug-resistant HIV amongst patients taking antiretroviral therapy in the Canadian province of British Columbia.
December 14, 2009
|
POZ Magazine
The transmission of drug-resistant strains of HIV has dropped dramatically in Vancouver, according to a study published January 1 in Clinical Infectious Diseases.
September 21, 2009
|
Aidsmap
People with HIV who have developed resistance to 3TC (lamivudine) can still achieve viral load suppression using boosted protease inhibitor regimens that include 3TC as part of the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) "backbone", researchers reported this week at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
July 22, 2009
|
Canadian Business
A genetic approach to determining HIV tropism can be used to effectively identify patients who will respond to treatment with the CCR5 antagonist maraviroc, according to new data presented today at the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa.
November 30, 2007
|
24 Hours
Tomorrow, people in Vancouver and around the world will wear a red ribbon tomorrow to celebrate World AIDS Day. 24 hours examines the lives of three people who tell the story of HIV/AIDS in our city.
October 16, 2007
|
Pfizer
Pfizer Canada is announcing today two significant healthcare research investments in British Columbia totaling $4.25 million.
Copyright BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital
608 - 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
General Telephone: 604-806-8477 | Fax: 604-806-9044
Email: info@cfenet.ubc.ca